Agios Pharmaceuticals, Inc. (AGIO) Stock

Healthcare · Biotechnology · Member of Other US Stocks

Agios Pharmaceuticals, Inc. (AGIO) closed at USD 30.97 on 2026-10-14, a change of -28.7 % over the past year, with a market capitalization of USD 1.93B.

Agios Pharmaceuticals, Inc. recent closing prices

The most recent trading day is not shown. For full charts and indicators use the analysis page.

Agios Pharmaceuticals, Inc. key figures

Previous close

USD 30.97 (2026-10-14)

1-year change

-28.7 %

Market cap

USD 1.93B

Enterprise value

USD 1.34B

P/E ratio (trailing)

-4.61

P/E ratio (forward)

-8.04

EPS (trailing)

-7.01

EPS (forward)

-4.02

PEG ratio

n/a

Price to book

1.88

Revenue growth

259.3 %

Earnings growth

n/a

Dividend per share (trailing)

0.00

Short ratio

7.21

Employees

539

Analyst consensus (third-party)

buy

Source: Yahoo Finance via yfinance. Data may be delayed, incomplete or incorrect.

About Agios Pharmaceuticals, Inc.

Agios Pharmaceuticals, Inc., a biopharmaceutical company, discovers and develops medicines in the field of cellular metabolism in the United States. Its lead product includes PYRUKYND (mitapivat), an activator of wild-type and mutant pyruvate kinase (PK), enzymes used for the treatment of hemolytic anemias in adults with PK deficiency. The company's PYRUKYND product is also used for the treatment of sickle cell disease that is in phase 3 clinical trial; for the treatment of PK deficiency in pediatric patients; and AQVESME for the treatment of adult patients with non-transfusion dependent and transfusion-dependent alpha- or beta-thalassemia. In addition, it developed tebapivat, a PK activator for the treatment of lower-risk myelodysplastic syndrome and sickle cell disease; AG-181, a phenylalanine hydroxylase stabilizer for the treatment of phenylketonuria (PKU); and AG-236, an siRNA in-licensed from Alnylam, targeting the transmembrane serine protease 6 (TMPRSS6) gene for the treatment of polycythemia vera. Agios Pharmaceuticals, Inc. was incorporated in 2007 and is headquartered in Cambridge, Massachusetts.

Technical indicators and comparison

Show RSI, MACD, EMA, CCI and ADX for Agios Pharmaceuticals, Inc. and compare it with other stocks.